UNASSIGNED: The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced @entity978 ( @entity978 ), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 @entity1 enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and @entity1349 ( @entity1349 ). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for @entity1349 . An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P  =  0  0001) and @entity1349 (P  <  0  0001)]. IPS-3 outperformed the IPS-7 on risk prediction for both FFP and @entity1349 by model fit and discrimination criteria. Using reclassification calibration, 18% of IPS-7 low risk @entity1 were re-classified as intermediate risk and 13% of IPS-7 intermediate risk @entity1 as low risk. For @entity1 with advanced @entity978 , the IPS-3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned.

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced XXXX in the modern era.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity978 :: (MESH:D006689,Disease) :: ['Hodgkin lymphoma']
